microdosing glp 1 perimenopause reddit GLP-1 Agonists in Perimenopause: Unique Risks and Potential Opportunities Study Reveals Unknown GLP-1 Side

Across age groups, current GLP-1 use is highest among those ages 50-64 (22%) when compared to younger and older adults

Kuo, and Michael S

(1996, Journal of Endocrinology) reported IGF-1 LR3 was 1.5-2x more potent than equimolar native IGF-1 for body weight gain, organ growth, and anti-catabolic effects when continuously infused in normal and dexamethasone-treated rats

AHK-CU is primarily used topically and does not have the same research base for injectable use that GHK-CU does

Key Contraindications (Both) Active malignancy or recent cancer history, pregnancy, breastfeeding, uncontrolled diabetes, severe pituitary disease

Several proteins involved in ER stress and apoptosis are also altered in expression by riboflavin deficiency